news aktuell GmbH

nal von minden: Did my vaccine work? New rapid test for the determination of vaccination success.

Share
Am I really protected against the coronavirus now? This is a question asked by many after receiving a vaccination. The medtech company nal von minden from Moers in Germany has now developed a rapid test that can reliably detect antibodies against COVID-19 pathogens in blood. The NADAL® COVID-19 S1-NAb Test is now available all over Europe.

(Moers, Germany): “People want clarity once they been vaccinated against coronavirus: They want to know if it has worked“ says Thomas Zander, CEO of nal von minden GmbH. Depending on the particular vaccine used, the COVID-19 vaccines offer 70% or more protection from the disease – but not 100%.


If the vaccine has ‘worked’, the body produces human antibodies against the disease. “These antibodies ensure that, in the event of exposure, the disease pathogens – the coronaviruses – would be readily identified and quickly repelled. Rather like the police on alert.”

These antibodies can be found in human blood and, if present, are easily detectable. With the NADAL® COVID-19 S1-NAb Test, the process takes just a few minutes. Thomas Zander explains: “Our new rapid test for the detection of coronavirus antibodies can be carried out by your GP in the future, as the test is currently only for professional use. A tiny prick of the finger is enough. The little drop of blood is added to the accompanying test cassette, and results can be read within 15 minutes.”

The new rapid test has already been comprehensively studied in the USA and China. “In the USA and China the vaccination programmes are more progressed, so the first studies were carried out there,” says Zander. “Further quality studies at German research centres will follow shortly.” It has been confirmed that the antibody test works for all kinds of vaccines (BioNtech, AstraZeneca, Johnson&Johnson, Sinovac and Moderna).

Coronavirus vaccinations usually take place across two appointments, and the new rapid test can be carried out either two weeks after the first vaccination, or two weeks after the second, says Thomas Zander. “Those who produce an immune response following the first vaccine – which can cause, for example, mild cold-like symptoms – can first wait until after the second vaccination.” Of course, the test can also be carried out weeks or even months afterwards, as nobody yet knows how long the vaccinations protect us against coronaviruses.

Contacts

Gabriele Hellwig, info@hellwig-pr.de

Images

About news aktuell GmbH

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589http://www.newsaktuell.de

news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Germany’s pharmacies under pressure: Statistical Yearbook 2025 now available16.7.2025 12:00:23 CEST | Press release

(Berlin, Germany) – ABDA – Federal Union of German Associations of Pharmacists has released the Statistical Yearbook “German Pharmacies: Figures, Data, Facts 2025”. The publication offers a comprehensive overview of the latest trends in the pharmaceutical and healthcare sectors in Germany and beyond. It shows that the number of pharmacies has decreased again. At the end of 2024 there were 17.041 pharmacies in Germany, which is the lowest number since the end of the 1970s. One of the main reasons for the increasing number of pharmacy closures is the economic difficulties many pharmacies are facing. Since the pharmacy remuneration has not been elevated in the past 12 years, around 25 percent of German pharmacies have earnings below 75.000 Euros a year. Around 7 percent of German pharmacies made losses in 2024. Those and other relevant facts and figures are shown on more than 130 pages in a revamped design of the new Statistical Yearbook – with several features that make the content easie

FEV Group: Generative AI accelerates homologation: FEV simplifies country-specific type approval processes10.7.2025 11:23:00 CEST | Press release

Aachen – Vehicle development doesn’t end with technical readiness: The road to global market launches is only complete once homologation has been successfully achieved. The increasing complexity of national regulations poses growing challenges to OEMs and suppliers. FEV addresses these with an innovative, AI-based approach: The company-wide used ‘FEV GenAI Hub’ significantly simplifies and accelerates the analysis of regulatory requirements across different global markets, offering time and cost savings that can provide customers with a decisive competitive edge.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye